songül keskin kavak

Dr. songül keskin kavak


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2024 in Supportive Care in Cancer
Verified
Journal Article
Open access
PDF file
SKsongül keskin kavak
songül keskin kavak
EKEngin Eren Kavak
Engin Eren Kavak
Objective: To evaluate the effects of complete decongestive therapy (CDT) on cancer-related fatigue, sleep quality, and lymphedema-specific quality of life using validated and reliable questionnaires in cancer patients being commendable. Material and methods: This prospective study includes 94 patients who had postmastectomy lymphedema syndrome. The demographic characteristics of the patients were recorded. The participants’ stages of lymphedema (The International Society of Lymphology), Hirai Cancer Fatigue Scale (HCFS) score, Pittsburgh Sleep Quality Index (PSQI) Global score, lymphedema-specific quality of life questionnaire (LYMQOL-ARM) score, and Global health status were recorded before and after CDT. Results: The mean age of the patients was 58.49 ± 10.96 years. Strong correlations were found between the severity of edema and global health status. There was a significant positive relationship between the HCFS score, PSQI Global score, LYMQOL-ARM score, and CDT. After decongestive physiotherapy, the majority of the lymphedema stages were downstaging (p < 0.05), respectively. There was also a trend toward improvement in general well-being (p < 0.05). Conclusion: Cancer-related fatigue and sleep disturbance can persist for years after surgery in women with breast cancer. This can negatively affect the patient physically, socially and cognitively. Our study, which is the first study to investigate the HCFS score in postmastectomy patients and the relationship between PSQI Global score and CDT. The findings identify the risk factors that affect these outcomes in women with lymphedema and can provide valuable insights for targeted interventions and improved patient care.

15 January 2024 in Turkish Journal of Physical Medicine and Rehabilitation
Verified
Journal Article
Open access
FAFikriye Figen Ayhan
Fikriye Figen Ayhan
AÇAyşegül Demirci Çoban
Ayşegül Demirci Çoban
AKAyça Utkan Karasu
Ayça Utkan Karasu
BKBelgin Karaoğlan
Belgin Karaoğlan
EÇEce Çınar
Ece Çınar
MDMeltem Dalyan
Meltem Dalyan
Objectives: This study aimed to evaluate the effects of the combined hydrolyzed type 2 collagen, methylsulfonylmethane (MSM), glucosamine sulfate (GS), and chondroitin sulfate (CS) supplement on knee pain intensity in patients with knee osteoarthritis (OA). Patients and methods: This multicenter, observational, noninterventional study included 98 patients (78 females, 20 males; mean age: 52.8±6.5 years; range, 40 to 64 years) who had Grade 1-3 knee OA between May 2022 and November 2022. The patients were prescribed the combination of hydrolyzed type 2 collagen, MSM, GS, and CS as a supplement for knee OA. The sachet form of the combined supplement containing 1250 mg hydrolyzed type 2 collagen, 750 mg MSM, 750 mg GS, and 400 mg CS was used once daily for two consecutive months. Patients were evaluated according to the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Visual Analog Scale (VAS)-pain, and Health Assessment Questionnaire (HAQ). Patients were scheduled to visit for follow-up four weeks (Visit 2) and eight weeks (Visit 3) after Visit 1 (baseline; day 0 of the study). Results: For the VAS-pain, WOMAC, WOMAC-subscale, and HAQ scores, the differences in improvement between the three visits were significant (p<0.001 for all). The patient compliance with the supplement was a median of 96.77%, both for Visit 2 and Visit 3. Conclusion: The combination of hydrolyzed type 2 collagen, MSM, GS, and CS for eight weeks in knee OA was considered an effective and safe nutritional supplement.

2 February 2024 in The Laryngoscope
Verified
Journal Article
Closed access
SKsongül keskin kavak
songül keskin kavak
ADArzubetül Duran
Arzubetül Duran
SDSibel Ünsal Delialioğlu
Sibel Ünsal Delialioğlu
LALale Aktekin
Lale Aktekin

1 April 2024 in Turkish Journal of Osteoporosis
Verified
Journal Article
Closed access
SKsongül keskin kavak
songül keskin kavak
LALale Aktekin
Lale Aktekin
EKEngin Eren Kavak
Engin Eren Kavak
BSBurcu Sevingül
Burcu Sevingül
MÖMerve Önoğul
Merve Önoğul

9 January 2025 in Journal of Medical and Health Studies
Verified
Journal Article
Open access
PDF file
MDMurat Doğan
Murat Doğan
SKsongül keskin kavak
songül keskin kavak
Given the autoimmune and inflammatory nature of Sjögren's Syndrome(SS), it is essential to identify reliable indicators to monitor disease progression and inform treatment strategies. This study aims to evaluate the potential of the Systemic Immune-Inflammation Index (SII) as a biomarker for assessing disease activity in SS. A prospective analysis was conducted on two groups: the first comprising 52 patients diagnosed with SS and the second a healthy control group. SII values were calculated using the following formula: platelet count multiplied by the neutrophil-to-lymphocyte ratio. The degree of disease activity was gauged according to the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) criteria. This study examines the correlations between SII and several clinical and patient-reported outcome measures, including various inflammatory markers. Compared to the control group, the SS patient cohort displayed slightly elevated SII levels (p = 0.04). The SII exhibited a correlation with elevated levels of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), suggesting its potential as a marker of systemic inflammation. Nevertheless, the observed correlation between SII and ESSDAI scores (r = 0.0903) was weak and not statistically significant (p = 0.524). Although SII values were higher in SS patients and correlated with systemic inflammation markers, no statistically significant relationship was observed between these values and disease activity, as measured by ESSDAI.Thus, while SII may reflect systemic inflammation, its utility as a marker for disease activity in SS remains limited. Further studies are needed to elucidate its role in clinical settings.

30 September 2024 in Heliyon
Verified
Journal Article
Open access
SKsongül keskin kavak
songül keskin kavak
EKEngin Eren Kavak
Engin Eren Kavak
The primary aim of our prospective study was to assess the impact of Dropped Head Syndrome (DHS), a rare condition in Head and Neck Cancer (HNC) clinics, on patients' functional status and body image. Our secondary aim is to investigate the relationship between head and neck lymphoedema (HNL) and DHS, which will be examined for the first time in the literature. We conducted a study involving 47 patients, aged between 18 and 75, who had been diagnosed with HNC, and exhibited clinical symptoms of DHS for at least 12 months. The staging of HNL was assessed using the MD Anderson Cancer Center HNL (MDACC HNL) staging system. We also administered The Total Functional Scale (TFS) which was a subscale of EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30) and the Body Image Scale (BIS). In the study, it was observed that the BIS was significantly lower in patient groups aged 50 and over (p = 0.0495), those with a laryngectomy (p = 0.0002), those who had undergone bilateral neck dissection (p = 0.0291), and particularly in patients with stage 2–3 lymphedema (p < 0.0001). Similarly, it was noted that passive cervical extension limitation had a statistically significant impact on both the BIS (p < 0.0001) and the TFS (p < 0.0001). It was also found that BIS (p < 0.0001) and TFS (p < 0.0001) improved in the late postoperative period (12 months ≤) and this improvement was statistically significant. In this study, we found statistical relationships between age, laryngectomy, surgery procedures, lymphedema stages, passive cervical extension limitations, total functional score, and BIS. Early diagnosis of DHS allows for supportive care and physiotherapy methods, which can lead to improvement. HNL and DHS should be prevented to improve quality of life and body image and increase survival. Therefore, further research with a much larger patient population is needed.